Clinical Trials › NCT05171972
Active, Not Recruiting
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
Sponsored by University of Southern California
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 40
Target enrollment
1
U.S. states
Jan 2022
Start date
Jun 2025
Expected completion
Interventions / Treatments
Ofatumumab
Conditions studied
Relapsing Remitting Multiple Sclerosis
Where this trial is running (1 site)
California1 site
Los Angeles
Participating MS centers on MS Buddy (1)
USC Multiple Sclerosis Comprehensive Care Center
Los Angeles, CA
Los Angeles, CA
MS centers in California
Compare treatment centers near a trial site by center type, providers and trials.
View California centersThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.